CTOs on the Move

SalioGen Therapeutics

www.saliogen.com

 
SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

SalioGen Therapeutics raised $20M on 02/18/2021

Similar Companies

ABclonal

Based in Massachusetts, ABclonal is a dynamic and growing provider of biology research reagents and services. With scientists from world-class universities, we thrive to improve the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS Prep Kits and molecular enzymes.

Celerion Inc

Celerion Inc is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SangStat Medical Corporation

SangStat Medical Corporation is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kezar Life Sciences

Kezar co-founder Christopher Kirk, Ph.D. began his work on the unique function of the immunoproteasome at Proteolix in 2005, while working on the compound that would become the successful multiple myeloma drug KYPROLIS™ (carfilzomib). As VP of Research at Onyx Pharmaceuticals, which acquired Proteolix in 2009, Christopher led the efforts to develop the first selective inhibitors of the immunoproteasome and designed multiple studies demonstrating their profound immunomodulatory effects. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential. In 2014, Christopher and Kezar co-founder John Fowler began developing the business plan for Kezar, acting on a longstanding desire to work together and build a world-class company. In 2015, John and Christopher raised $23M and negotiated a worldwide, exclusive license agreement with Amgen for the Onyx immunoproteasome inhibitor patent estate. Now underway, John and Christopher are excited to leverage their complementary skill sets to build Kezar into a leader in small molecule drug development.

Prescott Medical Communications Group

Prescott Medical Communications Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.